Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAT1 | O14929 | 2/20 | 0.47 |
| ▸ | EP300 | Q09472 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.45 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.45 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222496 | 0.93 | TRPV1 (0.46) | HAT1EP300TRPV1SNCALMNA | |
| SCHEMBL7232847 | 0.92 | HAT1 (0.52) | HAT1EP300TRPV1SNCALMNA | |
| SCHEMBL7231452 | 0.89 | TRPV1 (0.46) | HAT1EP300TRPV1PRKAB2PRKAG1 | |
| SCHEMBL7231259 | 0.87 | TRPV1 (0.48) | HAT1EP300TRPV1SNCALMNA | |
| SCHEMBL7222215 | 0.85 | TRPV1 (0.47) | HAT1EP300TRPV1POLBSNCA | |
| SCHEMBL7232958 | 0.84 | TRPV1 (0.47) | HAT1EP300TRPV1PRKAB2PRKAG1 | |
| SCHEMBL7224015 | 0.84 | TRPV1 (0.44) | HAT1EP300TRPV1POLBSNCA | |
| SCHEMBL7222939 | 0.83 | TRPV1 (0.43) | TRPV1POLBSNCALMNAL3MBTL1 | |
| SCHEMBL7233757 | 0.82 | TRPV1 (0.45) | TRPV1POLBSNCALMNAL3MBTL1 | |
| SCHEMBL7224328 | 0.80 | SNCA (0.45) | POLBSNCALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | claimed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | claimed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | claimed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | HAT1 2001/4885EP300 2259/4885TRPV1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.